Ali was instrumental in transitioning Tetratherix from a University research project to a tangible corporate entity. Ali developed Tetratherix’s technology during his PhD at the University of Sydney. Ali’s biochemical and entrepreneurial aptitude provide both the technological and commercial expertise upon which Tetratherix is based.

Terence’s Chemical Engineering background and his pervious experiences as CTO and Production Manager of two biomedical start-up companies provide the expertise necessary to manage Tetratherix’s production and further product development. Terence was instrumental in securing the capital investments, necessary to co-found Tetratherix. Terence will oversee all future business and product development of the company.

With Medical Science and Business degrees, Will’s started his career working in the business analysis function within one of Australia’s largest device manufacturers – Cochlear, before briefly moving into financial services & healthcare equities in Europe and the US. Upon returning to Australia, Will has worked across many markets of medical technology including orthopaedics, spine, biologic regeneration and interventional cardiology. Will obtained the role of Sales Manager for Medtronic and launched InfuseTM in Australia and New Zealand. Will also established Healthgate – an online services business for consumer management of chronic disease which was exited in 2009.

David co-founded investment firm Ryder Capital in 2008 and is a principal of the Ryder Innovation Fund, LP an early-stage venture capital fund specialising in medtech and technology opportunities. David has over 20 years’ experience in corporate finance, M&A, and investment advisory. He holds a Bachelor of Arts (Economic History), Bachelor of Laws (Hons) and is a Fellow of the Financial Services Institute of Australasia. Prior to co-founding Ryder, David held executive positions at Kleinwort Benson (UK Corporate Finance), Merrill Lynch & Co (London) investment bank and from 2004 – 2008 was the Australian managing director of US-based life sciences investment bank GMCG, LLC where he advised a number of Australian life science, biotech, and healthcare companies on M&A, financing, and strategy.

After graduating with a science degree (neurosc.) from Macquarie University, Jeff worked in the pharmaceutical industry within bone regeneration technology for a number of years. Following this Jeff moved into the medical device sector, managing sales functions for businesses within the spinal and orthopaedic markets. Jeff then launched a spinal technology business – AustSpine – in 2007. AustSpine was acquired by LifeHealthcare in 2010 and Jeff worked as the General Manager of the Spine Division until 2012. Jeff has continued to manage medical technology projects, distribution and investments across neural stimulation, interventional cardiology, orthopaedic software and biologic innovation.

Professor David Currow is a Fellow of the Australian Academy of Health and Medical Sciences (FAHMS). Professor Currow is an expert in translational research and the Chief Cancer Officer of NSW and Chief Executive Officer of the Cancer Institute NSW. Professor Currow is passionate about the use of minimally invasive techniques, to enhance patients’ health outcome post surgeries and other treatments. Professor Currow is past president of the Clinical Oncological Society of Australia and Palliative Care Australia. Professor Currow has served on the American Society of Clinical Oncology and been on faculty for the Australia & Asia Pacific Clinical Oncology Research Development workshops (ACORD). Professor Currow provides Trimph with scientific expertise in the fields of clinical trial design and public health priorities.

Dr Dax Calder is a member of Tetratherix’s clinical advisory team. Dax is a specialist periodontist with teaching positions at the University of Sydney and University of Western Australia. Dr Calder has spent more than 20 years of his professional career trying to simplify and improve techniques relating to dental implant surgeries and bone augmentation procedures.

Rob McInnes holds the position of Board Secretary, Licensing Executives Society International. For nearly a decade, Rob has been ranked as Australia’s highest recommended patent and technology licensing lawyer. He specializes in the commercialisation of novel technologies, and in the intellectual property-related aspects of major corporate transactions. He is an expert in the structuring and negotiation of contracts for the development and commercialisation of innovations.

Aoifa Brogan is a professional medical device regulatory affairs and quality management specialist with more than 15 years of experience across all device classes and therapeutic areas. Aoifa held various Regulatory Affairs roles living and working in Europe, the US and Australia. Aoifa was a senior regulatory affair specialist in multinational companies including Medtronic Ltd. Aoifa has been instrumental in establishing Tetratherix’s Quality Management System, obtaining ISO13485:2016 accreditation and clinical development strategy.